|
Mutation Information
|
Mutation Site
|
L180M |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.M204I+rt.L180M;rt.M204V+rt.L180M;rt.S202G+rt.M204V+rt.L180M;rt.V173L+rt.M204V+rt.L180M;rt.T184L+rt.I169T+rt.M204V+rt.L180M;rt.S202G+rt.I169T+rt.M204V+rt.L180M;rt.N236T+rt.A181T+rt.V173L+rt.S202I+rt.M204V+rt.L180M;rt.V173L+rt.M204I+rt.L180M;rt.M250L+rt.V173L+rt.V207S+rt.M204I+rt.L180M;rt.S202G+rt.T184I+rt.M204V+rt.L180M;rt.V207L+rt.S202G+rt.M204V+rt.L180M;rt.S213T+rt.M204V+rt.S202G+rt.L180M;rt.M250V+rt.M204I+rt.L180M;rt.Q215H+rt.S202G+rt.M204V+rt.L180M;rt.M204V+rt.M204I+rt.L180M |
|
Genotype/Subtype
|
B;C |
|
Relevant Drug
|
entecavir (ETV);lamivudine (LAM);telbivudine (LDT) |
|
Country
|
China |
Literature Information
|
PubMed PMID
|
28017671
|
|
Disease
|
HBV infection
|
|
Published Year
|
2017 |
|
Journal
|
Journal of global antimicrobial resistance |
|
Title
|
Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014). |
|
Author
|
Meng T,Shi X,Gong X,Deng H,Huang Y,Shan X,Shan Y,Huang A,Long Q |
|
Evidence
|
The 3TC resistance rate increased from 39.8% in 2010 to 56.6% in 2013, before decreasing to 49.5% in 2014, evidence of a lagging effect of l-nucleoside consumption. M204I, N236T and L180M+M204V+V173L/S202G were the most common substitutions for l-nucleoside (3TC and LdT), ADV and ETV genotypic resistant phenotypes, respectively.
|
|
|
HBV Mutation Detail Information